Navigation Links
BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
Date:8/19/2007

ase includes forward looking statements, which are based on certain assumptions and reflects management's current expectations. These forward looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMaxx Systems Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
3. Performance Comparisons of Commercial RT-PCR Systems
4. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
5. In Vivo Signal Transduction Pathway Reporting Systems
6. Improved Vectors for PathDetect Trans-Reporting Systems
7. Genetic Reporter Systems
8. Genetic Reporter Systems
9. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
10. Separation Reproducibility With the BioLogic Chromatography Systems
11. Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3